BioSpace News Archive

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company’s chief executive officer and president, will present at Guggenheim’s Genomic Medicines and Rare Disease Days on Monday, April 3, 2023, at 10:45 a.m. ET.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) today reported financial results for the fourth quarter and full-year ended December 31, 2022, and provided a corporate update.

Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in a virtual fireside chat at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days on Tuesday, April 4th at 10:45 am ET, as well as 1x1 meetings with investors.

ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”) today announced an exclusive multi-year licensing agreement of intellectual property from UC San Francisco (UCSF) through its Innovation Ventures group to develop and commercialize a radially branching cellular delivery device for use both in the Operating Room under fluoroscopy/CT guidance and under MRI guidance.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it has initiated CATALYST, a 1,000-patient, Phase 4 trial examining the prevalence of hypercortisolism in patients with difficult to control type 2 diabetes.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it will release its fourth quarter 2022 financial results along with its Form 10-K on Friday, March 31, 2023.

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the fourth quarter and full-year 2022 and summarized recent business highlights.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced that it has commenced an underwritten public offering of its ordinary shares, no par value.

Antengene Corporation Limited today announced its full-year 2022 financial results and provided updates on key events and achievements since the start of 2022.

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Division of Pulmonology, Allergy and Critical Care Advisory Committee meeting on May 11, 2023 to review the new drug application (NDA) for neffy®.